{
 "@context" : "http://schema.org",
  "id" : "http://bio2rdf.org/drugbank:DB00073",
  "type" : "Drug",
  "alternateName" : "Ig gamma-1 chain C region",
  "description" : "Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids",
  "doseSchedule" : "10 mg Solution form with intravenous route",
  "legalStatus" : "approved",
  "manufacturer" : "Roche",
  "mechanismOfAction" : "The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.",
  "name" : "Rituximab",
  "schema:sameAs" : "https://www.drugbank.ca/drugs/DB00073",
  "schema:url" : "https://www.drugbank.ca/drugs/DB00073"
}